Land: Israel
Språk: engelsk
Kilde: Ministry of Health
VELMANASE ALFA
KAMADA LTD, ISRAEL
A16AB15
POWDER FOR SOLUTION FOR INFUSION
VELMANASE ALFA 10 MG/VIAL
I.V
Required
CHIESI FARMACEUTICI S.P.A., ITALY
VELMANASE ALFA
Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha mannosidosis.
2021-08-18
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Lamzede 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 10 mg of velmanase alfa*. After reconstitution with 5 mL water for injections (WFI), one mL of the solution contains 2 mg of velmanase alfa (10 mg/5 mL). For the full list of excipients, see section 6.1. *Velmanase alfa is produced in mammalian Chinese Hamster Ovary (CHO) cells using recombinant DNA technology. 3. PHARMACEUTICAL FORM Powder for solution for infusion White to off-white powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis (see sections 4.4 and 5.1). _ _ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The treatment should be supervised by a physician experienced in the management of patients with alpha-mannosidosis or in the administration of other enzyme replacement therapies (ERT) for lysosomal storage disorder. Administration of Lamzede should be carried out by a healthcare professional with the ability to manage ERT and medical emergencies. Posology The recommended dose regimen is 1 mg/kg of body weight administered once every week by intravenous infusion at a controlled speed. For infusion rate see section “Method of administration”. _Special populations _ _ _ _Renal or hepatic impairment _ No dose adjustment is necessary for patients with renal or hepatic impairment. _Elderly _ No data are available and no relevant use in elderly patients is described. _Paediatric population _ No dose adjustment is necessary for the paediatric population. 2 Method of administration For intravenous infusion use only. Instructions on reconstitution of the medicinal product before administration The reconstituted solution should be clear. Do not use if opaque particles are observed or if the solution is discoloured (see section 6.6). The reconstituted solution of Lamzede should be administered using an infusion set equipped with a pump and Les hele dokumentet